New Marketplace
Clip
Drug Market Exclusivity Periods: Helpful/Harmful? (02:18)

Pharmaceutical manufacturers profit during market exclusivity periods, when no generics can compete with their drug. Evidence from the economics literature shows that innovation responds to these profits, along with market size; when we expand market size by insuring more people or paying more, we see more innovation.

Sometimes that innovation is impossible to walk away from, according to economist Amitabh Chandra — and someone still must pay the price. What if the new drug is a cure? “It’s going to be hard, very, very hard, to walk away from cures,” says Chandra. “The pharmaceutical company knows that, and so they’re going to charge and get a very high price.” But without the budget to pay for those drugs, we will have to walk away from them, “which is going to introduce tremendous anxiety in patients and in voters, which is why we have to think about alternative models.”

Another issue to consider is, what type of innovation do we want? A cure for hepatitis C would receive the same type of exclusivity period as a new form of eczema treatment, for example — and one of those seems a lot more valuable than the other. “Why do we give manufacturers the exact same incentives to build these drugs?” asks Chandra.

From the NEJM Catalyst event Navigating Payment Reform for Providers, Payers, and Pharma, held at Harvard Business School, November 2, 2017.

More From New Marketplace
Payer-Provider Partnerships Produce Better Quality Outcomes - community health plan / physician partnership

New Research Shows How Payer-Provider Partnerships Can Accelerate Adoption of Evidence-Based Care

Five best practices that are replicable and scalable are facilitating improved clinical and financial outcomes today.

30-Day Mortality Rates at Non-Teaching and Major Teaching Hospitals 2013-2014 - value-based care at academic medical centers

What Value-Based Payment Means for Academic Medical Centers

Academic medical centers must become as dedicated to advancing operational and clinical efficiency as they have been to advancing the science of medicine.

Medicare Compared to Private Spending Cumulative Growth 2009-2019 - traditional Medicare coverage

Redesigning Medicare to Work for Everyone

A proposal to improve the Medicare benefit package.

Pronovost04_pullquote payer interoperability data exchange

Promoting Interoperability: Roles for Commercial Payers

Interoperability is a business imperative for enhancing value in health care, and providers and payers must collaboratively meet the demands for data exchange.

Health Care Snapshot - Chinese Health Care and U.S. Health Care

Perspective from the East: Health Care in China

Context is the key to understanding China’s health care system and its emphasis on population health.

GordonWang01_pullquote - digital health care China

Digital Health Care in China: Benefits and Pitfalls

China’s experience offers insights for integrating digital and non-digital health care services.

Dale04_pullquote_disrupting the value-based vs fee-for-service payment model

Disrupting the Payment Model

We should modernize our payment mechanisms to reflect the reality of our digitally enabled lives.

Percentage of Patients Choosing a Reference-Based Pricing Facility for Knee or Hip Replacement Surgery - 2008-2012 - value-based benefit designs

The Evidence for High-Value Benefit Designs

Innovative models are showing promise, but limited transparency and peer-reviewed research hamper expansion.

New Evidence on Stemming Low-Value and Overprescribing - Nudgind Physicians Toward Better Prescribing Practices

New Evidence on Stemming Low-Value Prescribing

New research suggests that deploying strong and surprising messages could help to address overprescribing of opioids and other drugs.

Wang01_pullquote medical devices - medical device innovation in China

Accelerating Medical Device Innovation in China

Promoting collaboration between clinicians, researchers, device-makers, and regulators.

Connect

A weekly email newsletter featuring the latest actionable ideas and practical innovations from NEJM Catalyst.

Learn More »

Topics

Value Based Care

210 Articles

New Research Shows How Payer-Provider Partnerships…

Five best practices that are replicable and scalable are facilitating improved clinical and financial outcomes…

Medicare and Medicaid

127 Articles

What Value-Based Payment Means for Academic…

Academic medical centers must become as dedicated to advancing operational and clinical efficiency as they…

What Value-Based Payment Means for Academic…

Academic medical centers must become as dedicated to advancing operational and clinical efficiency as they…

Insights Council

Have a voice. Join other health care leaders effecting change, shaping tomorrow.

Apply Now